
Mirroring Senate counterparts, House committee advances PBM reforms
The House Energy & Commerce Committee advanced multiple bills to the House floor in a seven-hour hearing Wednesday, some of which included measures to address drug pricing transparency and PBMs.
The highlights included two bills, among other healthcare measures, that would advance accountability around PBMs and on drug pricing, including the embattled 340B program. One bill, also known as the “Promoting Access to Treatments and Increasing Extremely Needed Transparency,” or PATIENT Act, would ban spread pricing where PBMs can charge that state more than they reimburse pharmacies. That same ban was included in a Senate bill that also recently advanced out of committee.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters